Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560958 | 0.89 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL29508434 | 0.89 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL14483921 | 0.89 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL24214307 | 0.88 | CTSK (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL1343403 | 0.88 | CTSK (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL6296123 | 0.88 | CTSK (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL29399499 | 0.87 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL8211606 | 0.87 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL5147736 | 0.87 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL939021 | 0.87 | CTSK (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024198077-A1 | AMINO ACID DERIVATIVE AND PREPARATION METHOD THEREFOR, AND METHOD FOR USING AMINO ACID DERIVATIVE AS INTERMEDIATE TO SYNTHESIZE L-GLUFOSINATE-AMMONIUM | 南京华狮新材料有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724766-A | Amino acid derivative, preparation method thereof and method for synthesizing L-glufosinate-ammonium as intermediate | 南京华狮新材料有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-10919840-B2 | Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials | SEIKAGAKU CORPORATION (JP) | 2021-02-16 | — | — | US | disclosed |
| EP-3101064-B1 | DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL | SEIKAGAKU KOGYO CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20190345312-A1 | DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS | SEIKAGAKU CORPORATION (JP) | 2019-11-14 | — | — | US | disclosed |
| US-20170001948-A1 | DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS | SEIKAGAKU CORPORATION (JP) | 2017-01-05 | — | — | US | disclosed |
| EP-3101064-A1 | DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL | Seikagaku Corporation (JP) | 2016-12-07 | — | — | EP | disclosed |
| CN-103153968-B | Triazole derivative and pharmaceutical composition containing same and having analgesic effect | SHIONOGI & CO.,LTD. (JP) | 2016-02-03 | — | — | CN | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001948-A1 | DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS | SAT1, ACMSD, ADM2 | CYP1A2 3928/4885CYP2C9 2588/4885CYP2C19 3401/4885 |
| US-10919840-B2 | Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials | SAT1, ACMSD, ADM2 | CYP1A2 3928/4885CYP2C9 2588/4885CYP2C19 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.